Summary: In a phase 1 mechanistic trial in adults with type 2 diabetes, tirzepatide improved the clamp disposition index (combining insulin secretion and sensitivity) substantially more than placebo and significantly more than semaglutide, explaining its strong glucose-lowering seen in later trials.
PICO Summary
| Element | Detail |
|---|---|
| Population | 117 adults with type 2 diabetes for at least 6 months on metformin (39 per active arm, 24 placebo analysed), two centres in Germany. |
| Intervention | Subcutaneous tirzepatide 15 mg once weekly for 28 weeks (dual GIP/GLP-1 agonist). |
| Comparison | Semaglutide 1 mg once weekly or placebo. |
| Outcome | Clamp disposition index rose by 1.9 pmol·mL·min⁻¹·kg⁻¹ with tirzepatide vs no change with placebo (ETD 1.92; 95% CI 1.59–2.24; p<0.0001), and significantly more than semaglutide (ETD 0.84; 0.46–1.21), reflecting greater gains in both insulin secretion and sensitivity. Tirzepatide also reduced glucose excursions, insulin, and glucagon more than semaglutide. Gastrointestinal events most common; no deaths. |
Tirzepatide islet function and insulin sensitivity
Phase 1 RCT · type 2 diabetes · 28 weeks
Tirzepatide raised the clamp disposition index far more than placebo and significantly more than semaglutide, giving a mechanistic basis for its stronger glucose-lowering. Findings are physiological, not clinical outcomes.
Expert Commentary
This is a small phase 1 study, but a mechanistically important one, and I read it as genuinely informative rather than merely preliminary because it uses the gold-standard clamp to ask why tirzepatide works so well, not just whether it does. The answer is satisfying: the dual agonist improved the disposition index, capturing both beta-cell function and insulin sensitivity, more than placebo by a wide margin and more than semaglutide too, with parallel reductions in glucagon and glucose excursions. That gives a coherent physiological story for the large HbA1c effects later seen in phase 3. My caution is about not overreading it. With fewer than forty patients per arm over 28 weeks, these are detailed metabolic measures in a selected population, not clinical outcomes, and the earlier site version’s language about achieving normoglycaemia and approaching remission goes further than a mechanistic clamp study can support. Can I use this with my patients? Indirectly, yes. It strengthens my confidence that tirzepatide’s advantage over a pure GLP-1 agonist is real and mechanism-based, which reinforces choosing it where beta-cell dysfunction and insulin resistance both dominate. But I would lean on the large outcome trials, not this, for actual prescribing decisions.
References
Heise T, Mari A, DeVries JH, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022;10(6):418–429. doi:10.1016/S2213-8587(22)00085-7